<DOC>
	<DOC>NCT00585741</DOC>
	<brief_summary>Fractionated radiotherapy induces an observable change in the proliferative activity as assessed by pre-treatment and early-treatment 18F-FLT PET imaging. This study is designed to investigate 18F-FLT as a PET imaging agent for predicting treatment effectiveness in several tumors and will serve as a pilot study to a planned PO1 submission</brief_summary>
	<brief_title>Pilot Study of 18F-FLT PET</brief_title>
	<detailed_description />
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<mesh_term>Alovudine</mesh_term>
	<criteria>Able to tolerate a PET/CT scan Age of 18 or older signed informed consent being considered for radiotherapy for treatment of CNS mets, Head and neck cancer, lung cancer, prostate cancer or esophageal cancer Prior XRT to site being studied severe claustrophobia or inability to tolerate PET/CT unable to provide written consent pregnant or breastfeeding women</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>